Research programme: HIV integrase inhibitors - Valerio Therapeutics
Alternative Names: BA 011; BA011FZ041; FZ 41; Integrase strand transfer inhibitors (ISTIs) - Valerio Therapeutics; QNL111Latest Information Update: 08 Sep 2023
Price :
$50 *
At a glance
- Originator BioAlliance Pharma
- Developer Valerio Therapeutics
- Class Quinolines
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 03 Sep 2014 Discontinued - Preclinical for HIV-1 infections in France (unspecified route)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 21 Feb 2007 Preclinical development is ongoing